Get the Stockscreener App
42.27
1.06%
0.4443
Kiniksa Pharmaceuticals International Plc stock is traded at $42.27, with a volume of 275.59K.
It is up +1.06% in the last 24 hours and down -2.86% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$41.83
Open:
$41.83
24h Volume:
275.59K
Relative Volume:
0.58
Market Cap:
$3.20B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-301.96
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+11.48%
1M Performance:
-2.86%
6M Performance:
+52.95%
1Y Performance:
+120.07%
1-Day Range:
$41.22
$42.75
1-Week Range:
$38.04
$42.75
52-Week Range:
$18.12
$44.42
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
42.27 | 3.17B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Risk Off: Can Kiniksa Pharmaceuticals Ltd reach all time highs this yearQuarterly Profit Summary & Consistent Income Trade Ideas - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Makes New $1.48 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
First Week of March 20th Options Trading For Kiniksa Pharmaceuticals International (KNSA) - Nasdaq
Kiniksa Pharmaceuticals International PLC (KNSA) Trading Down 4. - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Is Down 6.7% After Raising 2026 ARCALYST Revenue OutlookHas The Bull Case Changed? - simplywall.st
Kiniksa Pharmaceuticals appoints new chief operating and strategy officers - Investing.com
Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO - TipRanks
Kiniksa Pharmaceuticals appoints new chief operating and strategy officers By Investing.com - Investing.com UK
Kiniksa Pharmaceuticals International, plc Appoints Management Team, Effective January 10, 2026 - marketscreener.com
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - Defense World
Wedbush Raises Price Target for Kiniksa Pharmaceuticals (KNSA) | - GuruFocus
KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next - TechStock²
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Trading Down 5.6%Time to Sell? - MarketBeat
High Growth US Tech Stocks To Watch In January 2026 - simplywall.st
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Dow - GuruFocus
Kiniksa reports 62% growth in ARCALYST revenue, forecasts 2026 sales By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals Provides Corporate Update - TradingView — Track All Markets
Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - Defense World
Kiniksa Pharmaceuticals International, plc $KNSA Stock Holdings Reduced by Peregrine Capital Management LLC - MarketBeat
Insider Sell: Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmac - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells $502,680.00 in Stock - MarketBeat
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Down 6.2%Here's What Happened - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Voya Investment Management LLC - Defense World
Rice Hall James & Associates LLC Reduces Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) - Finviz
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Time to Buy? - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week HighTime to Buy? - MarketBeat
Barry Quart Sells 20,129 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock - MarketBeat
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $500,715, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $835,555, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Kiniksa Pharmaceuticals (KNSA) director records option exercise and share sale - Stock Titan
Kiniksa Pharmaceuticals (KNSA) COO reports option exercise and share sale - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 20,129 Shares - MarketBeat
US High Growth Tech Stocks to Watch - simplywall.st
Braidwell LP Sells 860,329 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Nebula Research & Development LLC Has $1.93 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells 42,841 Shares of Stock - MarketBeat
Kiniksa Pharma CFO Ragosa sells shares worth $1.77m By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals CFO Sells Shares - TradingView — Track All Markets
Jump Financial LLC Takes Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Walleye Capital LLC - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Fisher Asset Management LLC Has $2.83 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) - MarketBeat
Traders Buy High Volume of Call Options on Kiniksa Pharmaceuticals International (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quart Barry D | Director |
Dec 15 '25 |
Option Exercise |
10.36 |
20,129 |
208,536 |
32,675 |
| Quart Barry D | Director |
Dec 15 '25 |
Sale |
41.51 |
20,129 |
835,555 |
12,546 |
| Tessari Eben | CHIEF OPERATING OFFICER |
Dec 15 '25 |
Option Exercise |
8.83 |
6,000 |
52,980 |
28,714 |
| Tessari Eben | CHIEF OPERATING OFFICER |
Dec 15 '25 |
Sale |
41.56 |
12,048 |
500,715 |
16,666 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):